Ligand Out-Licenses China Rights for Three Liver Products to Nucorion
August 01, 2016 at 01:21 AM EDT
San Diego's Ligand Pharma formed a new company, Nucorion Pharma, that will develop three preclinical Ligand programs in China. Each of the programs use Ligand’s LTP (Liver Targeting Prodrug) technology. Nucorion, which is backed by Silver River Investors of Hong Kong, will also develop drug candidates licensed directly from Ohio State University. The company will develop anti-cancer and anti-viral products with an initial target of the China market. Nucorion raised $5 million in a Series A led by Silver River; Ligand invested $1 million and will own less than 20% of Nucorion. More details.... Stock Symbol: (NSDQ: LGND) Share this with colleagues: // //